Core Viewpoint - Company has received a medical device registration certificate for its Digoxin assay kit, which is expected to enhance its product line in the in vitro diagnostic sector and improve its market competitiveness [1] Group 1 - The product name is Digoxin Assay Kit (Magnetic Particle Chemiluminescent Immunoassay) [1] - The kit is designed for the quantitative measurement of Digoxin levels in human serum or plasma [1] - The registration certificate number is 京械注准20252400878 [1] Group 2 - The acquisition of the medical device registration certificate enriches the company's product offerings in the field of in vitro diagnostics [1] - This development is anticipated to positively impact the company's core competitiveness and market expansion capabilities [1] - The company expects this to have a favorable effect on its future operations [1]

Core Viewpoint - Jiukang Bio (300406) has received a medical device registration certificate for its digoxin assay kit from the Beijing Drug Administration, indicating a significant regulatory approval for the company’s product in the healthcare market [1] Company Summary - The digoxin assay kit is designed for the quantitative measurement of digoxin levels in human serum or plasma, which highlights the company's focus on developing diagnostic tools for critical health monitoring [1] Industry Summary - The approval of the digoxin assay kit reflects the growing demand for reliable diagnostic solutions in the healthcare industry, particularly in the area of cardiac health management [1]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-092 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | 地高辛测定试剂盒 （磁微粒化学发光 | 京 械 注 准 20252400878 | Ⅱ | 自批准之日起有效期 至 2030 年 10 月 16 日 | 本试剂盒用于体外定量 测定人血清或血浆中地 | | | 免疫分析法） | | | | 高辛（DIG）的含量。 | 关于取得医疗器械注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： 上述产品医疗器械注册证的取得，丰富了公司在体外诊断化学发光细分 领域产品线的品种，有利于进一步提升公司的核心竞争力和市场拓展能 ...

Group 1 - The core viewpoint of the news is that Jiukang Bio's stock performance and financing activities indicate a mixed outlook, with a slight increase in stock price but a significant net financing outflow on October 20 [1] - On October 20, Jiukang Bio's stock rose by 0.53%, with a trading volume of 31.75 million yuan. The net financing buy was -4.14 million yuan, indicating more financing repayment than new purchases [1] - As of October 20, Jiukang Bio's total financing and securities lending balance was 182 million yuan, with a financing balance of 181 million yuan, accounting for 2.34% of the circulating market value, which is below the 50th percentile level over the past year [1] Group 2 - As of June 30, Jiukang Bio had 18,500 shareholders, an increase of 21.57% from the previous period, while the average circulating shares per person decreased by 17.73% to 22,920 shares [2] - For the first half of 2025, Jiukang Bio reported operating revenue of 668 million yuan, a year-on-year decrease of 18.67%, and a net profit attributable to shareholders of 175 million yuan, down 30.01% year-on-year [2] - Since its A-share listing, Jiukang Bio has distributed a total of 1.214 billion yuan in dividends, with 585 million yuan distributed in the last three years [3]

Group 1 - Yonghe Co., Ltd. reported a net profit of 469 million yuan for the first three quarters, a year-on-year increase of 220.39% [1] - Jinli Permanent Magnet achieved a net profit of 515 million yuan, reflecting a year-on-year growth of 161.81% [1][2] - Sanhe Pharmaceutical Auxiliary's net profit increased by 8.28% year-on-year, reaching 133 million yuan [2] Group 2 - Jiahuan Technology experienced a net profit decline of 26.53%, totaling 55.35 million yuan [3] - Wuchan Huaneng reported a net profit decrease of 15.10%, amounting to 453 million yuan [3] - Chuan Investment Energy's net profit fell by 4.54%, totaling 4.22 billion yuan [4][5] Group 3 - Dayang Bio's net profit grew by 56.12%, reaching 80 million yuan [5] - Weili Medical reported a net profit increase of 14.94%, totaling 192 million yuan [6] - People's Tongtai's net profit decreased by 45.69%, amounting to 112 million yuan [7] Group 4 - Jiuhuan Bio received a medical device registration certificate for its NT-proBNP test kit [8] - Jincheng Pharmaceutical's subsidiary obtained a drug registration certificate for a specific injection [9] - Guangdian Yuntong's subsidiary acquired a money service operator license in Hong Kong [10] Group 5 - Dash Intelligent won a bid for a project worth 96 million yuan related to the Shijiazhuang subway [10] - Alloy Investment's net profit increased by 124.87%, reaching 7.26 million yuan [11] - Kaile Co., Ltd. reported a net profit growth of 159.14%, totaling 21.63 million yuan [12] Group 6 - Chuanjinno's net profit surged by 175.61%, reaching 304 million yuan [14] - Rijiu Optoelectronics reported a net profit increase of 36.54%, totaling 76.91 million yuan [15] - Dazhu CNC's net profit grew by 142.19%, amounting to 492 million yuan [15] Group 7 - Nairui Radar expects a net profit increase of 181% for the first three quarters [17] - Suzhou Tianmai successfully acquired land use rights for a new manufacturing project [19] - Aokai Pharmaceutical announced clinical research data for its innovative drug at a major conference [21][22] Group 8 - Jilin Aodong's subsidiary passed the consistency evaluation for a specific injection [24] - Qinxin Environment announced the resignation of a board member [25] - *ST Baoying is planning a change in control, leading to a stock suspension [26] Group 9 - Jianlang Hardware's director plans to reduce holdings by up to 500,000 shares [27] - Taihe Technology's director intends to reduce holdings by up to 606,000 shares [29] - Zhongyuan Securities announced a cash dividend of 0.008 yuan per share [31] Group 10 - Beijing-Shanghai High-Speed Railway plans to distribute a cash dividend of 0.0385 yuan per share [32] - Zhuhai Guanyu expects a net profit increase of 36.88%-55.54% for the first three quarters [34] - Shenglong Co., Ltd. reported a net loss of 72.95 million yuan for the first three quarters [36] Group 11 - Shuangyuan Technology plans to distribute a cash dividend of 0.125 yuan per share [38] - Shaanxi Guotou A reported a net profit increase of 6.6%, totaling 996 million yuan [40] - Sunshine Nuohua intends to invest 15 million yuan in a biotech company [41] Group 12 - Yangjie Technology's net profit increased by 45.51%, reaching 974 million yuan [42] - Xingwang Yuda reported a net profit growth of 260%, totaling 38.37 million yuan [43] - Tongyou Technology turned a profit with a net profit of 9.29 million yuan [44]

Core Viewpoint - The company, Jiukang Biological, has received a medical device registration certificate from the Beijing Drug Administration for its product, the N-terminal pro-brain natriuretic peptide precursor assay kit, utilizing magnetic microparticle chemiluminescent immunoassay technology [1] Group 1 - The product is officially recognized as a medical device, indicating regulatory approval and potential market entry [1] - The assay kit is designed for measuring N-terminal pro-brain natriuretic peptide, which is significant in diagnosing heart-related conditions [1]

Core Viewpoint - The company, Jiukang Biotechnology, has received a medical device registration certificate from the Beijing Drug Administration for its product, the N-terminal pro-brain natriuretic peptide precursor assay kit, which utilizes magnetic particle chemiluminescent immunoassay technology [1] Group 1 - The product is officially recognized as a medical device, indicating regulatory approval and potential market entry [1] - The assay kit is designed for measuring N-terminal pro-brain natriuretic peptide, which is significant in diagnosing heart-related conditions [1]

| 证券代码：300406 | 证券简称：九强生物 公告编号：2025-091 | | --- | --- | | 债券代码：123150 | 债券简称：九强转债 | 北京九强生物技术股份有限公司 关于取得医疗器械注册证书的公告 特此公告。 北京九强生物技术股份有限公司 董事会 2025年10月20日 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 北京九强生物技术股份有限公司（以下简称"公司"）于近日收到北京 市药品监督管理局颁发的《医疗器械注册证》，具体情况如下： | 序号 | 产品名称 | 注册证编号 | 注册 类别 | 注册证有效期 | 预期用途 | | --- | --- | --- | --- | --- | --- | | 1 | N 末端脑利钠肽前 体测定试剂盒（磁微 粒化学发光免疫分 | 京 械 注 准 20252400875 | Ⅱ | 自批准之日起有效期 至 2030 年 10 月 14 日 | 本试剂盒用于体外定量 测定人血清或血浆中 N 末 端 脑 利 钠 肽 前 体 | | | 析法） | | | | （NT-proBNP）的含量。 ...

证券日报网讯 10月10日晚间，九强生物发布公告称，公司于2025年10月10日召开第五届董事会第二十 次会议，会议审议通过了《关于聘任公司总经理的议案》，董事会同意聘任王永利先生为公司总经理， 任期自本次董事会会议通过之日起至第五届董事会任期届满时止。 （文章来源：证券日报） ...

Group 1 - Jieqiang Equipment has completed the acquisition of 51% stake in Shandong Carbon Seeking, which will now be included in the company's consolidated financial statements [1] - Tonghua Dongbao's insulin injection product has received marketing approval in Myanmar for diabetes treatment [1] - New Light Optoelectronics' actual controller plans to increase shareholding by 5 to 10 million yuan within six months [2] Group 2 - Far East Holdings received contracts worth 1.769 billion yuan in September [3] - Poly Developments reported a 1.84% decrease in signed sales amount in September, totaling 20.531 billion yuan [4] - ST Nuotai expects a net profit increase of 5.62% to 13.74% for Q3 2025 [7] Group 3 - Chongqing Port's controlling shareholder plans to merge with another entity, changing the controlling shareholder to Chongqing Logistics Group [9] - New Energy Company reported a 28.21% increase in cumulative power generation from January to September [11] - Dashiang Co. announced the resignation of its chairman due to personal reasons [12] Group 4 - Liao Port Co. announced the resignation of a non-executive director due to work changes [13] - Zhongzai Resources received a government subsidy of 5.33 million yuan, accounting for 23.72% of its audited net profit for 2024 [14] - Xiaoming Co. reported a sales revenue of 66.15 million yuan from chicken products in September [15] Group 5 - Tianyi Co. signed a framework contract worth 23.50 million yuan for e-business network terminal production [16] - Jingu Co. signed a strategic cooperation agreement with Ninebot Technology for lightweight materials [18] - Tianbang Foods reported a sales revenue of 634 million yuan from commodity pigs in September [20] Group 6 - Shaanxi Energy's subsidiary received an administrative penalty for safety violations, resulting in a fine of 940,000 yuan [22] - North Bay Port reported a 9% increase in cargo throughput in September [23] - Tangrenshen reported a sales revenue of 639 million yuan from pig sales in September [24] Group 7 - Dabeinong reported a sales revenue of 541 million yuan from pig sales in September [25] - Jiukang Bio obtained four medical device registration certificates [26] - Canan Co. invested 90 million yuan in structured deposits with a bank [27] Group 8 - Zhuhai Port reported a 5.44% decrease in cargo throughput in Q3 [28] - Jinli Yongmag expects a net profit increase of 157% to 179% for the first three quarters [29] - Huamao Logistics' controlling shareholder plans to increase shareholding by 64.5 to 129 million yuan [30] Group 9 - Dongjie Intelligent signed a 50 million yuan contract for intelligent warehousing in the steel industry [31] - Sais Technology signed a cooperation framework agreement with Volcano Engine for intelligent robotics [32] - Huadong Pharmaceutical's subsidiary received approval for clinical trials of a new drug targeting advanced solid tumors [34] Group 10 - TCL Technology completed the acquisition of 80% and 100% stakes in LG Display's subsidiaries for 11.088 billion yuan [34] - Shuangliang Energy won a 419 million yuan EPC project for cooling systems [36] - Ruina Intelligent announced plans for shareholders to reduce their stakes by up to 1.18% [38] Group 11 - Baodi Mining announced plans for shareholders to reduce their stakes by up to 5.45% [40] - Xinyi Technology's shareholders set the transfer price for shares at 328 yuan each [42] - Sunshine Power submitted an application for H-share listing on the Hong Kong Stock Exchange [44] Group 12 - Qisheng Technology's controlling shareholder plans to reduce their stake by up to 3.09% [46] - Wu Ming Kangde sold 30.3 million shares of Wu Ming He Lian through block trading [48] - Qiaoyin Co. announced plans for shareholders to reduce their stakes by up to 6% [49] Group 13 - Muyuan Foods reported a sales revenue of 9.066 billion yuan from commodity pigs in September [51] - Huawang Technology's shareholders plan to reduce their stakes by up to 1.1% [53] - Huaxin Xinchuang received a project notification from Lantu Automotive for display components [54] Group 14 - China Merchants Shekou reported a signed sales amount of 16.698 billion yuan in September [55] - Shao Neng Co. received approval for an antitrust review regarding a share acquisition [57] - Pengding Holdings reported a 6.21% increase in consolidated revenue in September [58] Group 15 - Ganfeng Lithium is advancing its solid-state battery commercialization and strategic investment in the energy storage sector [59]